Riskpilot← Back to searchSign inGet full accessAPOFARM AB
ABActiveOrg 5593011363Klagshamnsvägen 40Retail sale of pharmaceutical products · NACE 4773Est. 20214 employees
Revenue 2025
SEK 38,9M
+10% vs 2024
EBITDA margin
0.5%
-83% vs 2024
Equity ratio
1.3%
Financial strength
Net profit 2025
SEK -6K
-101% vs 2024
| Revenue | SEK 38,9M | +10% |
| EBITDA | SEK 196K | -83% |
| Net profit | SEK -6K | -101% |
| Total assets | SEK 8,4M | +15% |
| Equity | SEK 112K | -96% |
| Employees | 4 | — |
Legal name
APOFARM AB
Org number
5593011363
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
10 februari 2021
Share capital
SEK 50 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva apoteksverksamhet, försäljning av receptfria & receptbelagda läkemedel och handelsvaror samt därmed förenlig verksamhet.
Address
Klagshamnsvägen 40
Phone
+46732706724
Email
kundservice@apofarm.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 409 | 12 184 | 26 597 | 35 311 | 38 924 |
| Staff expenses | — | −1 265 | −1 808 | −2 390 | −2 699 |
| EBITDA | −124 | 390 | 913 | 1 163 | 196 |
| Depreciation & amort. | −10 | −90 | −107 | −114 | −114 |
| EBIT | −134 | 300 | 807 | 1 049 | 82 |
| Net financials | −12 | −68 | −56 | −33 | −82 |
| Profit before tax | −146 | 232 | 751 | 1 016 | −0 |
| Tax | −0 | −22 | −150 | −213 | −6 |
| Net profit | −146 | 210 | 601 | 803 | −6 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 578 | 5 216 | 6 460 | 7 336 | 8 441 |
| Equity | 214 | 2 123 | 2 484 | 2 888 | 112 |
| Long-term debt | 1 000 | 764 | 479 | 204 | 0 |
| Short-term debt | 364 | 2 329 | 3 496 | 4 245 | 8 329 |
| Total debt | 1 364 | 3 093 | 3 975 | 4 448 | 8 329 |
EBITDA margin
0.5%
This company
15.8%
Market median
-97% vs market
20212025
Equity ratio
1.3%
This company
38.2%
Market median
-97% vs market
20212025
Return on equity
-5.3%
This company
18.4%
Market median
-129% vs market
20212025
Net profit margin
-0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
4.61×
This company
1.12×
Market median
+312% vs market
20212025
Debt / equity
74.57×
This company
0.62×
Market median
-11927% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-02-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AV | Audit | 2024 |
JB Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Chairman | 2022 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of APOFARM AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Veronica Elisabeth Blom | Audit | 0 companies |
| Jehon Baftijaj | Chief Executive Officer | 0 companies |
| Dan Olof Johansson | Chairman | 0 companies |
| Marc van Loenhout | Board of Directors | 0 companies |
| Tom Sebastian Johansson | Deputy Board Member | 0 companies |
| Vincentius Maria Maar | Deputy Board Member | 0 companies |